Compare Msci Inc (MSCI) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs ResMed Inc. — how do they compare? Msci Inc trades at $564.09 (market cap $40.38B), while ResMed Inc. trades at $230.22 (market cap $31.89B). The key difference: Msci Inc is the larger of the two by market cap, and Msci Inc pays the higher dividend (1.48%). Which is the better fit depends on your goals — on Pluang, investors hold Msci Inc for 82 Days and ResMed Inc. for 51 Days on average.
| MSCI | RMD | |
|---|---|---|
Market Cap | $40.38B | $31.89B |
Volume | 414,140 | 618,314 |
Sector | Financials | Health |
52-Week High | $643.83 | $277.88 |
52-Week Low | $511.84 | $182.82 |
Typical Hold Time | 82 Days | 51 Days |
Enterprise Value | $46.54B | $31.24B |
Dividend Yield | 1.48% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $565.05, up 1.74% on the day, with a neutral technical signal and key resistance near $567. The company reported Q2 2026 earnings of $4.94 per share, slightly missing estimates, but maintains strong fundamentals with 40.73% net income margin and revenue growth to $3.13 billion in 2025. Recent news includes the completion of the First Street acquisition and upcoming Q3 2026 earnings call.
The outlook is supported by high analyst bullishness (74% buy ratings) and a consensus price target of $701.71, implying significant upside. Risks include high valuation multiples (P/E 30.37) and substantial long-term debt of $4.51 billion. Earnings growth and execution on strategic acquisitions are critical for sustaining momentum.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
